HENLIUS (02696) saw its shares climb nearly 5% during the morning trading session. At the time of writing, the stock was up 4.1%, trading at HK$58.4, with a turnover of HK$19.1632 million.

On the news front, HENLIUS recently held a successful offline investigator meeting for the HLX22-GC-301 study in San Francisco, USA.

The meeting focused on the company's international multi-center Phase III clinical trial, HLX22-GC-301, which is evaluating the investigational novel epitope anti-HER2 monoclonal antibody HLX22 in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive advanced gastric cancer.

Notably, HENLIUS also announced recently that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical trial for the combination of injectable HLX43, HLX07, and serplulimab injection for the treatment of advanced solid tumors.

HENLIUS plans to commence a Phase II clinical study of this combination therapy in China once the necessary conditions are met.